Erlotinib is a reversible small-molecule ATP analogue which has been found to be most effective in advanced NSCLC patients with a tumor containing exon 19 deletions or a L858R mutation in exon 21 of the gene encoding the EGFR kinase domain [19,20]. Here, EGFR is linked to neoplasm.